Monoclonal antibody therapeutics with up to five specificities: Functional enhancement through fusion of target-specific peptides

The recognition that few human diseases are thoroughly addressed by mono-specific, monoclonal antibodies (mAbs) continues to drive the development of antibody therapeutics with additional specificities and enhanced activity. Historically, efforts to engineer additional antigen recognition into molec...

Descripción completa

Detalles Bibliográficos
Autores principales: LaFleur, David W., Abramyan, Donara, Kanakaraj, Palanisamy, Smith, Rodger G., Shah, Rutul R., Wang, Geping, Yao, Xiao-Tao, Kankanala, Spandana, Boyd, Ernie, Zaritskaya, Liubov, Nam, Viktoriya, Puffer, Bridget A., Buasen, Pete, Kaithamana, Shashi, Burnette, Andrew F., Krishnamurthy, Rajesh, Patel, Dimki, Roschke, Viktor V., Kiener, Peter A., Hilbert, David M., Barbas III, Carlos F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Landes Bioscience 2013
Materias:
Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3893231/
https://www.ncbi.nlm.nih.gov/pubmed/23575268
http://dx.doi.org/10.4161/mabs.23043

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3893231/
https://www.ncbi.nlm.nih.gov/pubmed/23575268
http://dx.doi.org/10.4161/mabs.23043

Ejemplares similares